Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection

J. Stone Doggett, Kayode K. Ojo, Erkang Fan, Dustin J. Maly, Wesley C. Van Voorhis

Research output: Contribution to journalArticlepeer-review

53 Scopus citations


Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

Original languageEnglish (US)
Pages (from-to)3547-3549
Number of pages3
JournalAntimicrobial agents and chemotherapy
Issue number6
StatePublished - Jun 2014
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection'. Together they form a unique fingerprint.

Cite this